Meta Ray-Ban Smart Glasses Launch

On March 31st, Road to VR broke the news that Meta is preparing two new Ray-Ban smart glasses variants specifically designed for prescription wearers, with pricing starting at $499. The following day, ArtificialInteligence.com confirmed the same figure and the same framing — prescription users, two models, five hundred dollars as the entry point. The timing here is worth noting: this landed right on the March 31 to April 1 boundary, which is not an ideal window for credibility. That said, both outlets are treating it straight, and the $499 price point aligns with where the existing Ray-Ban Meta lineup already sits. The prescription angle is the genuine news. Until now, smart glasses have largely assumed you either have perfect vision or are willing to wear contacts underneath them — a quiet exclusion that affects a significant portion of the population who might actually want these things.

If confirmed, here is what this means. Meta is no longer treating smart glasses as a lifestyle accessory for the minority with unaided vision — it is going after the prescription market directly, which in the United States alone represents over 150 million people. The $499 starting price keeps this in premium-but-accessible territory, roughly what someone already spends on a decent pair of prescription frames from an optician. The strategic implication is clear: Meta wants Ray-Ban smart glasses to become someone's only pair of glasses, not a second pair they occasionally swap to. That is a fundamentally different value proposition, and it removes one of the most practical objections regular users have had. Second-order effect — this puts pressure on every other wearable company that has been quietly ignoring the prescription problem, including whoever eventually brings a serious AR overlay product to market.

Watch for official Meta announcements or retailer listings that confirm the two model names and availability dates — and pay particular attention to whether optician partnerships are part of the rollout, since that infrastructure question will determine whether the prescription promise actually lands in practice.

NewsHive monitors these sources continuously. All signal titles above link to the original reporting.

Intelligence by NewsHive. Need help navigating what this means for your business? Contact GeekyBee →